Interleukin-6 (IL-6), a 26 kDa, alpha-helical protein, is produced locally in the nervous system by astrocytes, microglia, and neurons, and is important in activating infiltrating macrophages, regulating B cell growth and differentiation as well as inducing T cell responses (Frei

Interleukin‐6 (IL‐6) is produced by neurons, astrocytes, and microglia, and elevated levels of IL‐6 within the CNS have been documented in multiple neurological disorders including Alzheimer’s disease, stroke, epilepsy, attention deficit disorder, cerebral palsy, and multiple sclerosis. Here, we sought to understand how IL‐6 regulates microglial signal transduction and their immune properties. Using highly enriched cultures of neonatal murine microglia we show that IL‐6 alone has direct effects on microglia as it activates STAT3 and extracellular signal‐regulated kinase pathways in a time‐ and dose‐dependent fashion and it enhances interferon‐gamma (IFNγ)‐stimulated IL‐12 secretion. However, other immune properties were only weakly modulated by IL‐6 when administered without the soluble IL‐6 receptor (sIL‐6R). For instance, IFNγ‐induced expression of the co‐stimulatory molecule, CD40 was dependent on sIL‐6R administration. IL‐6 with or without sIL‐6R did not affect major histocompatability complex class II expression. In granulocyte–macrophage colony‐stimulating factor (GMCSF)‐induced dendritic cell‐like microglia, IL‐6/sIL‐6R and IFNγ stimulated an even greater increase in CD40 expression compared with primary microglia. Altogether, our results demonstrate that microglial responses to IL‐6 are not simple in that the effects of IL‐6 are context‐dependent. In particular, the presence or absence of sIL‐6R, IFNγ or GMCSF will alter the type and amplitude of their response.

[1]  S. Levison,et al.  Ciliary neurotrophic factor and interleukin‐6 differentially activate microglia , 2008, Journal of neuroscience research.

[2]  J. Scheller,et al.  Interleukin‐6 biology is coordinated by membrane‐bound and soluble receptors: role in inflammation and cancer , 2006, Journal of leukocyte biology.

[3]  P. Patterson,et al.  Potent pro-inflammatory actions of leukemia inhibitory factor in the spinal cord of the adult mouse , 2004, Experimental Neurology.

[4]  M. Michalopoulou,et al.  Soluble interleukin-6 receptor (sIL-6R) in cerebrospinal fluid of patients with inflammatory and non inflammatory neurological diseases. , 2004, Immunology letters.

[5]  Guang-Xian Zhang,et al.  Role of the IL-12/IL-23 system in the regulation of T-cell responses in central nervous system inflammatory demyelination. , 2004, Critical reviews in immunology.

[6]  Jonathan R. Enterline,et al.  Astrocytes produce CNTF during the remyelination phase of viral-induced spinal cord demyelination to stimulate FGF-2 production , 2003, Neurobiology of Disease.

[7]  T. Chaiworapongsa,et al.  Intrauterine infection and the development of cerebral palsy. , 2003 .

[8]  D. Wesemann,et al.  Suppressor of Cytokine Signaling 1 Inhibits Cytokine Induction of CD40 Expression in Macrophages1 , 2002, The Journal of Immunology.

[9]  P. Ricciardi-Castagnoli,et al.  Granulocyte-Macrophage Colony-Stimulating Factor Induces an Expression Program in Neonatal Microglia That Primes Them for Antigen Presentation1 , 2002, The Journal of Immunology.

[10]  D. Barford,et al.  TYK2 and JAK2 Are Substrates of Protein-tyrosine Phosphatase 1B* , 2001, The Journal of Biological Chemistry.

[11]  Andrew L. Kung,et al.  Role of T-bet in Commitment of TH1 Cells Before IL-12-Dependent Selection , 2001, Science.

[12]  Josef M. Penninger,et al.  CD45 is a JAK phosphatase and negatively regulates cytokine receptor signalling , 2001, Nature.

[13]  N. Tanuma,et al.  Protein-tyrosine phosphatase PTPepsilon C inhibits Jak-STAT signaling and differentiation induced by interleukin-6 and leukemia inhibitory factor in M1 leukemia cells. , 2000, The Journal of biological chemistry.

[14]  V. Nguyen,et al.  Involvement of STAT-1 and Ets Family Members in Interferon-γ Induction of CD40 Transcription in Microglia/Macrophages* , 2000, The Journal of Biological Chemistry.

[15]  P. Igaz,et al.  Soluble interleukin-6 receptor (sIL-6R) makes IL-6R negative T cell line respond to IL-6; it inhibits TNF production. , 2000, Immunology letters.

[16]  S. Tóth,et al.  Generation of 'truncated' interleukin-6 receptor (IL-6R) mRNA by alternative splicing; a possible source of soluble IL-6R. , 1999, Immunology letters.

[17]  H. Bluethmann,et al.  Strongly compromised inflammatory response to brain injury in interleukin‐6‐deficient mice , 1999, Glia.

[18]  B. Hilliard,et al.  IL-6-deficient mice are resistant to experimental autoimmune encephalomyelitis: roles of IL-6 in the activation and differentiation of autoreactive T cells. , 1998, Journal of immunology.

[19]  I. Kerr,et al.  Activation of the protein tyrosine phosphatase SHP2 via the interleukin-6 signal transducing receptor protein gp130 requires tyrosine kinase Jak1 and limits acute-phase protein expression. , 1998, The Biochemical journal.

[20]  K. Frei,et al.  IL‐6‐deficient mice resist myelin oligodendrocyte glycoprotein‐induced autoimmune encephalomyelitis , 1998, European journal of immunology.

[21]  H. Baumann,et al.  Protein Tyrosine Phosphatase 2 (SHP-2) Moderates Signaling by gp130 but Is Not Required for the Induction of Acute-Phase Plasma Protein Genes in Hepatic Cells , 1998, Molecular and Cellular Biology.

[22]  P. Patterson,et al.  Leukemia Inhibitory Factor Is Expressed in Astrocytes Following Cortical Brain Injury , 1997, Experimental Neurology.

[23]  L. Adorini,et al.  IL-12 production by central nervous system microglia is inhibited by astrocytes. , 1997, Journal of immunology.

[24]  J. Chi,et al.  High expression of tumor necrosis factor-α and interleukin-6 in periventricular leukomalacia ☆ ☆☆ ★ ★★ ♢ , 1997 .

[25]  G. Guazzi,et al.  IL-6 detection in multiple sclerosis brain , 1997, Journal of the Neurological Sciences.

[26]  S. Rose-John,et al.  The function of the soluble IL-6 receptor in vivo. , 1996, Immunology letters.

[27]  J. Antel,et al.  Soluble tumor necrosis factor receptor inhibits interleukin 12 production by stimulated human adult microglial cells in vitro. , 1996, The Journal of clinical investigation.

[28]  H. Link,et al.  Shift from anti- to proinflammatory cytokine profiles in microglia through LPS- or IFN-gamma-mediated pathways. , 1996, Neuroreport.

[29]  R. Romero,et al.  Interleukin-6 concentrations in umbilical cord plasma are elevated in neonates with white matter lesions associated with periventricular leukomalacia. , 1996, American journal of obstetrics and gynecology.

[30]  P. Kivisäkk,et al.  Increased interleukin-6 mRNA expression in blood and cerebrospinal fluid mononuclear cells in multiple sclerosis , 1996, Journal of Neuroimmunology.

[31]  Peter Riederer,et al.  Interleukin-1β and interleukin-6 are elevated in the cerebrospinal fluid of Alzheimer's and de novo Parkinson's disease patients , 1995, Neuroscience Letters.

[32]  P. Heinrich,et al.  The soluble human IL-6 receptor. Mutational characterization of the proteolytic cleavage site. , 1994, Journal of immunology.

[33]  G. Yancopoulos,et al.  Association and activation of Jak-Tyk kinases by CNTF-LIF-OSM-IL-6 beta receptor components. , 1994, Science.

[34]  A. Stalder,et al.  Reactive gliosis as a consequence of interleukin-6 expression in the brain: studies in transgenic mice. , 1994, Developmental neuroscience.

[35]  L. Mucke,et al.  Neurologic disease induced in transgenic mice by cerebral overexpression of interleukin 6. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[36]  J. R. Unnerstall,et al.  The expression of CNTF message and immunoreactivity in the central and peripheral nervous system of the rat. , 1992, Brain research. Developmental brain research.

[37]  H. Thoenen,et al.  Regional distribution, developmental changes, and cellular localization of CNTF-mRNA and protein in the rat brain , 1991, The Journal of cell biology.

[38]  U. Schreiter-Gasser,et al.  Interleukin‐6 and α‐2‐macroglobulin indicate an acute‐phase state in Alzheimer's disease cortices , 1991, FEBS letters.

[39]  W. Fiers,et al.  Is amyloidogenesis during Alzheimer's disease due to an IL-1-/IL-6-mediated 'acute phase response' in the brain? , 1991, Immunology today.

[40]  A. Reder,et al.  Cytokine levels in the cerebrospinal fluid and serum of patients with multiple sclerosis , 1991, Journal of Neuroimmunology.

[41]  A. Fontana,et al.  Interleukin-6 is elevated in plasma in multiple sclerosis , 1991, Journal of Neuroimmunology.

[42]  R. Zinkernagel,et al.  On the cellular source and function of interleukin 6 produced in the central nervous system in viral diseases , 1989, European journal of immunology.

[43]  S. Levison,et al.  Ciliary neurotrophic factor and interleukin‐6 differentially activate microglia , 2008, Journal of neuroscience research.

[44]  J. Scheller,et al.  Interleukin‐6 biology is coordinated by membrane‐bound and soluble receptors: role in inflammation and cancer , 2006, Journal of leukocyte biology.

[45]  P. Patterson,et al.  Potent pro-inflammatory actions of leukemia inhibitory factor in the spinal cord of the adult mouse , 2004, Experimental Neurology.

[46]  M. Michalopoulou,et al.  Soluble interleukin-6 receptor (sIL-6R) in cerebrospinal fluid of patients with inflammatory and non inflammatory neurological diseases. , 2004, Immunology letters.

[47]  C. Gutiérrez,et al.  High expression of tumor necrosis factor alpha receptors in peripheral blood mononuclear cells of obese type 2 diabetic women. , 2004, European cytokine network.

[48]  Guang-Xian Zhang,et al.  Role of the IL-12/IL-23 system in the regulation of T-cell responses in central nervous system inflammatory demyelination. , 2004, Critical reviews in immunology.

[49]  Jonathan R. Enterline,et al.  Astrocytes produce CNTF during the remyelination phase of viral-induced spinal cord demyelination to stimulate FGF-2 production , 2003, Neurobiology of Disease.

[50]  T. Chaiworapongsa,et al.  Intrauterine infection and the development of cerebral palsy , 2003, BJOG : an international journal of obstetrics and gynaecology.

[51]  D. Wesemann,et al.  This information is current as Macrophages Cytokine Induction of CD 40 Expression in Suppressor of Cytokine Signaling 1 Inhibits , 2002 .

[52]  D. Barford,et al.  TYK2 and JAK2 Are Substrates of Protein-tyrosine Phosphatase 1B* , 2001, The Journal of Biological Chemistry.

[53]  Andrew L. Kung,et al.  Role of T-bet in Commitment of TH1 Cells Before IL-12-Dependent Selection , 2001, Science.

[54]  Josef M. Penninger,et al.  CD45 is a JAK phosphatase and negatively regulates cytokine receptor signalling , 2001, Nature.

[55]  N. Tanuma,et al.  Protein-tyrosine phosphatase PTPepsilon C inhibits Jak-STAT signaling and differentiation induced by interleukin-6 and leukemia inhibitory factor in M1 leukemia cells. , 2000, The Journal of biological chemistry.

[56]  V. Nguyen,et al.  Involvement of STAT-1 and Ets Family Members in Interferon-γ Induction of CD40 Transcription in Microglia/Macrophages* , 2000, The Journal of Biological Chemistry.

[57]  P. Igaz,et al.  Soluble interleukin-6 receptor (sIL-6R) makes IL-6R negative T cell line respond to IL-6; it inhibits TNF production. , 2000, Immunology letters.

[58]  S. Tóth,et al.  Generation of 'truncated' interleukin-6 receptor (IL-6R) mRNA by alternative splicing; a possible source of soluble IL-6R. , 1999, Immunology letters.

[59]  H. Bluethmann,et al.  Strongly compromised inflammatory response to brain injury in interleukin‐6‐deficient mice , 1999, Glia.

[60]  B. Hilliard,et al.  IL-6-deficient mice are resistant to experimental autoimmune encephalomyelitis: roles of IL-6 in the activation and differentiation of autoreactive T cells. , 1998, Journal of immunology.

[61]  I. Kerr,et al.  Activation of the protein tyrosine phosphatase SHP2 via the interleukin-6 signal transducing receptor protein gp130 requires tyrosine kinase Jak1 and limits acute-phase protein expression. , 1998, The Biochemical journal.

[62]  K. Frei,et al.  IL‐6‐deficient mice resist myelin oligodendrocyte glycoprotein‐induced autoimmune encephalomyelitis , 1998, European journal of immunology.

[63]  H. Baumann,et al.  Protein Tyrosine Phosphatase 2 (SHP-2) Moderates Signaling by gp130 but Is Not Required for the Induction of Acute-Phase Plasma Protein Genes in Hepatic Cells , 1998, Molecular and Cellular Biology.

[64]  P. Patterson,et al.  Leukemia Inhibitory Factor Is Expressed in Astrocytes Following Cortical Brain Injury , 1997, Experimental Neurology.

[65]  L. Adorini,et al.  IL-12 production by central nervous system microglia is inhibited by astrocytes. , 1997, Journal of immunology.

[66]  G. Guazzi,et al.  IL-6 detection in multiple sclerosis brain , 1997, Journal of the Neurological Sciences.

[67]  J. Chi,et al.  High expression of tumor necrosis factor-alpha and interleukin-6 in periventricular leukomalacia. , 1997, American journal of obstetrics and gynecology.

[68]  S. Rose-John,et al.  The function of the soluble IL-6 receptor in vivo. , 1996, Immunology letters.

[69]  R. Romero,et al.  Interleukin-6 concentrations in umbilical cord plasma are elevated in neonates with white matter lesions associated with periventricular leukomalacia , 1996 .

[70]  J. Antel,et al.  Soluble tumor necrosis factor receptor inhibits interleukin 12 production by stimulated human adult microglial cells in vitro. , 1996, The Journal of clinical investigation.

[71]  H. Link,et al.  Shift from anti- to proinflammatory cytokine profiles in microglia through LPS- or IFN-gamma-mediated pathways. , 1996, Neuroreport.

[72]  R. Romero,et al.  Interleukin-6 concentrations in umbilical cord plasma are elevated in neonates with white matter lesions associated with periventricular leukomalacia. , 1996, American journal of obstetrics and gynecology.

[73]  P. Kivisäkk,et al.  Increased interleukin-6 mRNA expression in blood and cerebrospinal fluid mononuclear cells in multiple sclerosis , 1996, Journal of Neuroimmunology.

[74]  P Riederer,et al.  Interleukin-1 beta and interleukin-6 are elevated in the cerebrospinal fluid of Alzheimer's and de novo Parkinson's disease patients. , 1995, Neuroscience letters.

[75]  P. Heinrich,et al.  The soluble human IL-6 receptor. Mutational characterization of the proteolytic cleavage site. , 1994, Journal of immunology.

[76]  G. Yancopoulos,et al.  Association and activation of Jak-Tyk kinases by CNTF-LIF-OSM-IL-6 beta receptor components. , 1994, Science.

[77]  A. Stalder,et al.  Reactive gliosis as a consequence of interleukin-6 expression in the brain: studies in transgenic mice. , 1994, Developmental neuroscience.

[78]  L. Mucke,et al.  Neurologic disease induced in transgenic mice by cerebral overexpression of interleukin 6. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[79]  J. R. Unnerstall,et al.  The expression of CNTF message and immunoreactivity in the central and peripheral nervous system of the rat. , 1992, Brain research. Developmental brain research.

[80]  H. Thoenen,et al.  Regional distribution, developmental changes, and cellular localization of CNTF-mRNA and protein in the rat brain , 1991, The Journal of cell biology.

[81]  U. Schreiter-Gasser,et al.  Interleukin‐6 and α‐2‐macroglobulin indicate an acute‐phase state in Alzheimer's disease cortices , 1991, FEBS letters.

[82]  W. Fiers,et al.  Is amyloidogenesis during Alzheimer's disease due to an IL-1-/IL-6-mediated 'acute phase response' in the brain? , 1991, Immunology today.

[83]  A. Reder,et al.  Cytokine levels in the cerebrospinal fluid and serum of patients with multiple sclerosis , 1991, Journal of Neuroimmunology.

[84]  A. Fontana,et al.  Interleukin-6 is elevated in plasma in multiple sclerosis , 1991, Journal of Neuroimmunology.

[85]  R. Zinkernagel,et al.  On the cellular source and function of interleukin 6 produced in the central nervous system in viral diseases , 1989, European journal of immunology.